Theravance Biopharma
TBPH
91 hedge funds and large institutions have $297M invested in Theravance Biopharma in 2015 Q2 according to their latest regulatory filings, with 13 funds opening new positions, 39 increasing their positions, 18 reducing their positions, and 12 closing their positions.
117% more repeat investments, than reductions
Existing positions increased: 39 | Existing positions reduced: 18
1% more funds holding
Funds holding: 90 → 91 (+1)
8% more first-time investments, than exits
New positions opened: 13 | Existing positions closed: 12
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
20% less capital invested
Capital invested by funds: $369M → $297M (-$72.1M)
70% less call options, than puts
Call options by funds: $77K | Put options by funds: $261K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AC
Armistice Capital
New York
|
+$7.17M |
| 2 |
BB
BB Biotech
Schaffhausen,
Switzerland
|
+$5.57M |
| 3 |
Renaissance Technologies
New York
|
+$4.09M |
| 4 |
CC
Clearline Capital
New York
|
+$3.79M |
| 5 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
+$3.45M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UBS AM
Chicago,
Illinois
|
-$8.18M |
| 2 |
GC
Guggenheim Capital
Chicago,
Illinois
|
-$3.75M |
| 3 |
State Street
Boston,
Massachusetts
|
-$2.2M |
| 4 |
First Manhattan
New York
|
-$1.96M |
| 5 |
NI
Numeric Investors
Boston,
Massachusetts
|
-$989K |
TBPH Hedge Fund Activity: Q2 2015 in Review
91 of the 3,730 institutional investors tracked by Wall St. Rank reported a position in Theravance Biopharma (TBPH) for Q2 2015, worth a combined $297M — down 20% from $369M a quarter earlier.
Buyers outnumbered sellers: 13 funds opened new TBPH positions and 12 closed out — a net gain of 1 holder — while 39 added to existing stakes and 18 trimmed.
The largest buyer was Armistice Capital, adding an estimated $7.17M. The largest seller was UBS AM, exiting entirely with an estimated $8.18M sold.
- 91 institutional investors held Theravance Biopharma (TBPH) as of Q2 2015, up from 90 in Q1 2015.
- Funds reported $297M of Theravance Biopharma stock for Q2 2015, down 20% quarter-over-quarter.
- 13 funds opened new Theravance Biopharma positions in Q2 2015 and 12 closed out, a net change of +1 holder.
- The largest Theravance Biopharma buyer in Q2 2015 was Armistice Capital, an estimated $7.17M added.
- The largest Theravance Biopharma seller in Q2 2015 was UBS AM, an estimated $8.18M sold.
Based on aggregated 13F filings for Q2 2015.